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Vaccines against human helminths are being developed but the choice of optimal parasitological end-
points and effect measures to assess their efﬁcacy has received little attention. Assuming negative
binomial distributions for the parasite counts, we rank the statistical power of threemeasures of efﬁcacy:vailable online 22 March 2011
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ratio of mean parasite intensity at the end of the trial, the odds ratio of infection at the end of the trial,
and the rate ratio of incidence of infection during the trial. We also use a modelling approach to estimate
the likely impact of trial interventions on the force of infection, and hence statistical power.We conclude
that (1) ﬁnal mean parasite intensity is a suitable endpoint for later phase vaccine trials, and (2) mass
effects of trial interventions are unlikely to appreciably reduce the force of infection in the community –
er – u
d.athematical model and hence statistical pow
of the population enrolle
. Introduction
Intestinal helminths infect more than one billion people
orldwide [1] and cause the loss of more than four million
isability-adjusted life years (DALYs) annually [2]. Themost impor-
ant genera are Ascaris, Trichuris, Ancylostoma, Necator, Enterobius
nd Schistosoma [2,3],while others include Taenia,Hymenolepis and
asciola. Current control efforts rely more heavily on chemother-
py than on sanitarymeasures [1,2,4]. However, there are concerns
bout the sustainability of periodic deworming on the basis of cost,
nd risk of drug resistance. This has prompted development of vac-
ines against intestinal parasites of humans [5]. Trials of vaccines
gainst hookworm have reached Phase I [6] while those against
nd Schistosoma japonicum and S. mansoni are in pre-clinical stud-
es [7–9]. Veterinary vaccines have also been developed against
asciola hepatica [10], Taenia spp and Echinococcus granulosus [11].
Intestinal helminths generally cause greatermorbidity at higher
nfection intensity [3,4], and the vaccines currently in development
re more likely to reduce the intensity of infections than to con-
er complete protection against infection. For these reasons, trial
ndpoints for such vaccines are likely to include measures of the
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intensityof infectionaswell as just thepresenceor absenceof infec-
tion. Such intensity endpointshavenot, so far, been commonlyused
as primary measures of efﬁcacy in vaccine trials. Trials of existing
vaccines against non-helminth parasitic diseases, notably malaria,
have concentrated on protection against infection considered as a
dichotomous variable: either infection of any intensity, or clinical
symptoms combined with infection above a speciﬁed threshold. In
trials in which the primary endpoint is the incidence of new infec-
tions, existing infections are usually cleared at the start of the trial,
and typical endpoints are thecumulativeproportion infected, or the
infection incidence rate [12–18]. If infection intensity is analysed
as an endpoint in itself, it is usually a secondary endpoint.
An exception is the Combination Bmalaria vaccine trial in Papua
New Guinea [19]. This is instructive because those subjects who
were free of parasitaemia throughout follow-up were not included
in the analysis, apparently because zeros were not accommodated
by the chosen analysis, which used logarithms of geometric mean
infection intensity. In the current paper we will use arithmetic
rather than geometric means to measure infection intensity. This
avoids problems with zeros but, more importantly, the arithmetic
mean has a closer link with the force of infection, i.e. the rate of
Open access under CC BY license.acquisition of infection. The force of infection is likely to be approx-
imately proportional to the total number of infectious parasites in
the community. In the case of hookworm, this is the total num-
ber of free-living larvae, which in turn is likely to be approximately
proportional to the total eggs excreted per unit time,which by deﬁ-
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ition is proportional to the arithmeticmeanegg count. By contrast,
he geometricmeanhas no clear relationwith the force of infection.
We will assess the statistical power of assessing efﬁcacy mea-
ures based upon the following endpoints: (i) arithmetic mean
arasite intensity at the end of the trial, (ii) dichotomous infec-
ion status (i.e., whether or not infected) during the trial, and (iii)
ncidence rate of ﬁrst infection following vaccination, based on
ime to ﬁrst infection. The corresponding efﬁcacy measures will
e (i) between-arm ratio of means, (ii) odds ratio and (iii) rate
atio. We will also consider the importance of the reduction in the
orce of infection in the trial population caused by clearing preva-
ent infections among trial participants at the start of the trial, and
accinating some of the population. The work has been motivated
y the design of preliminary studies and trials within the Human
ookworm Vaccine Initiative [20].
. Materials and methods
.1. Statistical power of potential efﬁcacy measures
We consider simple two-arm trial designs consisting of equal
umbers of individuals randomized between vaccinated and
nvaccinated arms. Any product administered to those in the
nvaccinated arm is assumed to be ineffective against the tar-
et infection. We rank the statistical power of ratio measures of
fﬁcacy based on the following three endpoints: (1) mean infec-
ion intensity at the end of the trial; (2) whether infected or not
t the end of the trial; and (3) incidence rate of ﬁrst infection
n the trial. We assume that infection intensity is estimated by
ounting parasites in a standard stool sample volume, and that
hese parasite counts can be described by a negative binomial dis-
ribution, as is commonly the case [21,22]. This distribution is a
eneralization of the Poisson. While the Poisson is mathematically
ased on an assumption of uniformity in the underlying level of
arasites indifferent individuals, thenegativebinomialhasanaddi-
ional parameter (usuallydenotedk)whichallowsgreater variance,
eﬂecting between-person heterogeneity in infection levels. We
xpress theparameters of theother twoendpoints in termsof those
f the negative binomial distribution. For each endpoint we obtain
he test statistic for comparing the vaccine and control arms, as the
atioof a relevant efﬁcacymeasuredividedby its standarderror. For
ean parasite intensity, the efﬁcacy measure is the ratio of means
etween the two arms; for dichotomous infection status, it is the
dds ratio; and for the incidence of ﬁrst infection, it is the rate ratio.
e further assume that there will be no waning of efﬁcacy during
he period of the trial. Appendix A shows the derivation of the cor-
esponding expected values of the test statistics which are denoted
mean, ZOR and ZRR. Higher absolute values of these Z statistics cor-
espond to greater evidence against the null hypothesis for a given
et of trial parameters (such as vaccine efﬁcacy) with assumed val-
es. We treat this as synonymous with greater statistical power,
lthough it is a simpler concept than pre-trial power calculation,
hich depends on the Z statistics under the null and alternative
ypotheses [23]. Trial duration does not enter directly into our cal-
ulations, although longer trials will tend to have larger infection
ntensities in the control arm, and hence higher efﬁcacy measures
under the above assumption of no vaccine waning).
The test statistics (Z) are expressed in terms of the negative
inomial’s mean () and dispersion (k) parameters. The latter is
ssociated with variance V via the relation V=+2/k, so lower
alues of k imply higher values of variance. For sample size calcu-
ations, the simplest assumption is that k holds a constant value
ver the different arms of the trial [24]. However, descriptive stud-
es often ﬁnd lower values of  to be associated with lower values
f k. We therefore also allow for this possibility within trials. Since29 (2011) 3686–3694 3687
the vaccine is assumed to reduce  from its pre-trial value, this
implies a smaller k in the vaccine arm, relative to control. So, an
assumption of such a relation between  and k is conservative, in
that it increases the variance, relative to the previous assumption
of constant k.
To quantify this reduction in k, weuse Taylor’s power law,which
is an empirical relation between mean and variance of population
numbers: V= ab [25,26]. Themagnitude of association is reﬂected
by the b parameter, while a is of less fundamental interest since it
depends on sampling effort. Equating this power lawwith the pre-
vious expression for V gives k=/(ab−1 −1), or k≈2−b/a [27].
Shaw [28] found that b was approximately 1.5 for many different
parasite taxa, including nematodes. For hookworm, this is con-
sistent with data from our studies conducted in Americaninhas
(Minais Gerais State, Brazil) [29], from which we estimated b=1.4
(95% conﬁdence interval 0.6–2.2). Hence we use a value of b=1.5
in our analysis, so that the value k1 in the trial arm is related to that
in the control arm by k1 = k0
√
1/0.
When calculating the test statistic for incidence (Z RR), we take
account of the fact that monitoring of new infections will not gen-
erally be continuous, so they will not be detected till the next
scheduled follow-upexamination. This increases the standarderror
of the rate ratio to an extent which depends on the frequency of
follow-up [30].
2.2. Impact on force of infection of trial interventions
The statistical power of a vaccine trial will depend in part on the
force of infection in the study area (i.e. rate of acquisition of infec-
tion). The greater the force of infection, the greater the expected
numberof infectionevents in the trial, and thegreater the statistical
power of the trial. However, the trial intervention(s), if efﬁcacious,
will tend to reduce this force of infection to below the pre-trial
value, even in the control arm, because their vaccinated neighbours
will, on average, be less infectious. For thepresentwork,we assume
that all infections are cleared at the start in both arms of the trial
(vaccine and control). Wemodify an existingmodel to quantify the
impact of these interventions on the time course of themean num-
ber of adultwormsper person, in both arms of the trial, and in those
people not participating. We assume that:
a proportion  of the study area’s population are trial participants,
half of these in the vaccine arm and half in the control arm;
the vaccine reduces acquisition of adult worms by a factor , and
this protection is assumed to last at least for the duration of the
trial.
For this analysis, we assumed k to be lower for lower values
of , via the relation derived above (k1 = k0
√
1/0). The model
equations are derived in Appendix B.
All calculationsweredoneusing the software S-Plus versions6.2
and 7, and R versions 2.5–2.7. In particular, the model’s differential
equations were solved numerically using the ‘odesolve’ package
in R.
3. Results
3.1. Statistical power of potential efﬁcacy measures
We consider three candidate efﬁcacy measures: ratio of mean
parasite intensity at the end of the trial, the odds ratio for being
parasite-positive at the end of the trial, and the incidence rate
ratio for incidence of infection (of any intensity) during the trial.
All three are expressed in terms of the parameters of the nega-
tive binomial distribution: the mean () and dispersion parameter
3688 N. Alexander et al. / Vaccine 29 (2011) 3686–3694
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Box: Worked example
We revisit the example given by Brooker et al. [24]. In the con-
trol arm of a trial, the ﬁnal mean number of hookworm eggs
counted per person is assumed to be0 = 72, with the negative
binomial dispersion parameter being k0 = 0.33. Themean in the
vaccine arm is assumed to be 30% less:1 = 72×(1− 0.3) = 50.4.
Assuming that k is proportional to the square root of the mean,
the vaccine arm has k1 = k0
√
1/0 ≈ 0.28.
The egg-positive prevalences in the control and vaccine arms
are then 83% and 76%, respectively (using the relevant equa-
tion in Appendix A), and the corresponding incidence rates are
1.78 and 1.44. These rates are expressed with trial length as
the unit. So if the trial takes 1 year to reach the given infec-
tion intensities, then the rates are per year. If the trial takes two
years to reach the same infection intensities, then the rates are
0.89/year and 0.72/year, respectively.
Comparing effect measures, the Z value for ratio of means –
i.e. the log ratio of means divided by its standard error – with
100 people per arm is Zmean =1.38. This is larger than the cor-
responding value for odds ratio (ZOR =1.20) and slightly larger
than those for rate ratio based on 3 surveys (ZRR =1.32) or con-
tinuous surveillance (ZRR =1.34). Finally, the sample size based
on ratio of means, for 90% power and 5% two-sided signif-
icance level, is 523 per arm, compared to 505 per arm withmean parasites seen
ig. 1. Relation between the proportion parasite-positive at the end of the trial, i
arasite intensity (), and the k dispersion parameter.
(Appendix A). The mean is of the number of parasites seen per
erson at each examination round. For example, for intestinal para-
ites, it could be themean of the total numbers of eggs actually seen
added up over possiblymultiple slides). For example, from a single
ato-Katz slide per person, the possible values of eggs seen are 0,
, 2, . . . and the possible values of eggs per gram are 0, 24, 48, . . ..
he negative binomial distribution can be ﬁtted to the former data
ut not the latter. However, if the resulting mean is, for example, 2
ggs per slide, this is easily converted to 48 eggs per gram. Larger
alues of k parameter imply a distribution of parasites between
eople which is more uniform (closer to Poisson). Equivalently, k is
maller when parasites are more clustered in smaller numbers of
eople. Hence, for a given mean parasite intensity, larger values of
correspond to larger prevalences, and larger incidence rates. This
s illustrated in Fig. 1.
To rank the statistical power of the three effect measures, we
alculate their Z statistics, i.e. the ratio of expected value to stan-
ard error. This is illustrated in Box , and in Fig. 2 for a range ofmean
ggs counted per person () in the control and intervention arms,
or a ﬁxed k of 0.5 and n=100 people per arm. Each of the effect
easures has a three-dimensional surface plot and a contour plot,
howing the same results in terms of its Z statistic. A Z value which
s larger in magnitude (i.e. farther from zero) produces a smaller p
alue and reﬂects greater statistical power. Fig. 2 shows that, for the
xed value of k=0.5, the ratio of means is more powerful than the
thermeasures. The nextmost powerful is the incidence rate ratio,
ollowed by the odds ratio. Little gain in power results from mea-
uring incidence continually as opposed to three follow-up surveys.
ne would expect the odds ratio to be less powerful than the inci-
ence rate ratio because,while both are based on infection status as
binary outcome, the odds ratio is based only on ﬁnal infection sta-
us, while the incidence also uses infection status at surveys during
he course of the trial.k=0.33 for both arms [24].
Similar patterns to those of Fig. 2 were seen for the other values
of ﬁxed k considered (0.1, 0.2 and1, not shown).However,when k is
allowed to varywith themean, then the ratio ofmeans is not always
the most powerful effect measure. Such an example is shown in
Fig. 3. Here, the incidence rate ratio is the most powerful, although
the differences between the four effect measures are small.
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Fig. 2. Surface and contour plots of Z statistics from four candidate effect measures.
The horizontal axes in the surface plots, and both axes in the contour plots, show
possible values of mean infection intensity (number of parasites seen per person) in
the two arms (‘0’ and ‘1’) of a trial with 100 people per arm and a ﬁxed value of 0.5
for negative binomial dispersion parameter (k). The vertical axis in the surface plot,
and the contour values in the contour plot, show Z statistics: the expected value of
the test statistic divided by its standard error. A Z statistic of 2 (or −2) corresponds
to a two-sided p value of 0.05, and Z=4 corresponds to p=0.00006. Comparing the
effect measures, a higher Z value for the same means indicates greater statistical
power. For any combination of mean infection intensity, the ratio of means has the
highest absolute value of Z, and so is the most powerful effect measure, followed by
the rate ratio. The ratio ofmeans achieves Z valuesmore than 20,while the others do
not reach Z=10.Whether the rate estimation is based on three examination rounds,
or continuous surveillance, makes little difference, as indicated by comparing their
Z values for any given combination of mean infection intensities in the two arms.
Finally, the odds ratio is slightly less powerful than the rate ratio. This can be seen,
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Fig. 3. For small values of k, the ratio of means is not always the most powerful
efﬁcacy measure. In this example, k is proportional to the square root of the mean
infection intensity, and equal to 0.5 when the mean is 100 (the highest value in the
[31]. Hence values of these two parameters are likely to be impor-or example, by noting that the latter reaches values of Z=±6 for slightly smaller
ifferences in means: these contours are further in from the upper left and bottom
ight corners.
.2. Mass effects of trial interventionsWe use the model developed in Appendix B to examine the
eduction in force of infectionwhich is caused by clearance of infec-
ions among participants at the start of the trial, and by the efﬁcacy
f the vaccine. Table 1 shows the default parameter values. For thisrange considered). Other parameters are as in Fig. 2. In the current ﬁgure, the rate
ratio is the most powerful efﬁcacy measure. To see this, note that, for example, the
rate ratio efﬁcacy measures reach Z values of 10 for some combinations of means,
while the other efﬁcacy measures do not.
model we assume that k is related to the mean. If, instead, k is
assumed to be ﬁxed and equal in the two arms, then, for large
means, the value of the Z statistic depends on the means largely
via the numerator, with the denominator being dominated by the
values of k (see the equation for Zmean in Appendix A). This implies
that the power is effectively the same for a given ratio of means,
irrespective of their magnitudes, which could well be misleading
given the empirical evidence against assuming a ﬁxed k.
Three examples of themodel output are shown in Fig. 4: the ﬁrst
two panels represent hookworm, and the rightmost one S. mansoni
(see parameters in Table 1).
In each case, as expected, the new equilibrium mean is lower
than the pre-trial equilibrium for unvaccinated people (whether in
the control arm or outside the trial), because their force of infec-
tion from neighbouring participants is reduced. This effect is small
when 10% of the study area’s population are included (left hand
panel), but appreciable when 50% are included (middle panel). In
each panel, the new equilibrium in the vaccine arm is lower still,
because the vaccine’s efﬁcacy is assumed to last indeﬁnitely. The
timescale for rebound to their respective new equilibria is simi-
lar in these two panels. By contrast, the new equilibrium level is
reached more slowly in the case of S. mansoni (right hand panel).
This is because the basic reproduction number (R0) is lower and
the adult worm lifespan is higher (Table 1), and it is the ratio of
these two quantities which controls the rate of spread of infectiontant in planning vaccine trials, especially if baseline estimates of
reinfection rates are not available.
Fig. 5 shows that, if a greater proportion of people are in the
trial, or the vaccine efﬁcacy is greater, then (a) the new equilibrium
3690 N. Alexander et al. / Vaccine 29 (2011) 3686–3694
Table 1
Default parameter values for the model of mass effects in vaccine trials.
Parameter Parasite Value Sources
R0 Basic reproduction number Hookworm 4 Ye et al. [54]. Other reported values are lower, e.g. 2–3 by Anderson
and May in their Table 16.3 [22], and approximately 2 by Bradley et al.
[33], but this higher value gives better agreement with our
unpublished data
S. mansoni 2.5 Woolhouse [55]
ω Death rate in humans 0.025/year
ω1 Death rate of adult worms Hookworm 0.2/year Loukas and Prociv [56]
S. mansoni 0.125/year To illustrate possible differences with hookworm we have chosen a
value which corresponds to a lifespan of 8 years, towards the upper
end of the following published estimates: 6–10.5 years by Fulford [57],
4–9, ≥8 and ≥16 estimated by Vermund et al. in different cohorts [58],
and 3–5years by Goddard and Jordan [59] and Anderson and May [22,
p. 438]
Grams of faeces per person per day 150 Towards the lower end of developed country estimates [60,61]
Eggs per female worm per day Hookworm 10,000 Bethony et al. [1]
S. mansoni 300 LoVerde et al. [62], Anderson and May [22]
* Equilibrium mean number of adult
worms per person
Hookworm 30 Calculated from mean of about 1000 eggs per gram (epg) of faeces in
Americaninhas (Brazil) [29], times 2 to include male worms, times
grams of human faeces per day (above), divided by eggs per female
worm per day (above)
S. mansoni 150 As above but using 150epg [29]
k Dispersion parameter for negative
binomial distribution of adult
worms per person, at the
equilibrium mean (*)
Hookworm 0.35 From Bradley et al. [33]. In Americaninhas (Brazil) some of the present
authors found k≈0.1 for egg counts [29] but the distribution of adult
worms was not estimated, As the mean varies, k is assumed to be
proportional to its square root
S. mansoni 0.35 As previous row. The k for S. mansoni egg counts in the study area was
approximately 0.2 [29]
d Strength of density dependence Hookworm 0.9791 Chosen to obtain stated value of *: d=1− (k/*)(R01/(k+1) −1)
S. mansoni 0.9977 As above
 Factor by which vaccine reduces
rate of acquisition of adult worms
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Fig. 4. Examples of model predictions of the change in mean parasite intensity over time. People in the trial, whether in the vaccine or placebo arm, are assumed to have any
initial infections cleared at baseline.
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tig. 5. The effect of vaccine efﬁcacy and proportion of population in the trial on (a)
he post-trial equilibriummean in the control arm (left panel) and (b) Z statistic for
he ratio of mean parasite intensity in vaccine/control arms (right panel).
ean is lower, and (b) the Z statistic is closer to the null value (i.e.
ess statistically signiﬁcant). Moreover, we can see from right hand
anel of Fig. 4 that the new equilibrium may not be approached
or several years, quite possibly longer than is feasible for a trial. In
uch circumstances, the Z values in the right hand panel of Fig. 5
ould over-estimate the statistical power of the trial.
. Discussion
The ﬁrst objective of the present work was to investigate the
tatistical properties of the between-arm ratio of mean parasite
ntensity at the end of a trial as an effect measure for vaccine trials,
suggestion we have made elsewhere [24]. The results show that,
or the range of parameters considered, and under the assumptions
ade, the ratio of means is often much more powerful than the
lternatives considered.However, therearealso situations inwhich
t is not the most powerful but, in those cases, the loss of power
elative to other effect measures is small.
The negative binomial distribution, which we assumed for par-
site counts, has proven to be a useful tool for analysing intensity
f human intestinal helminth infections [21,22,29,32–36]. Never-
heless, a better ﬁt to some datasets may be obtained by more
ophisticated distributions such as the zero-inﬂated negative bino-
ial [37,38]. As its name suggests, this is an elaboration of the
egative binomial distribution, allowing for an increased propor-
ion of parasite-negative individuals. The effect on the conclusions
f the current work would depend on the extent of the zero inﬂa-
ion, which is likely to be rather imponderable at the trial planning
tage. Although the current approach could be extended to other
istributions, the twoparametersof the standardnegativebinomial
llow trialists tomake assumptions for themean and variance, and
his is likely to be sufﬁcient in many situations.
It is surprising that ﬁtting a negative binomial distribution is not
he most powerful analysis when this distribution is, by assump-
ion, the one followed by the data. The fact that the ratio of means
ay be less powerful than the incidence rate ratio is explicable by
he fact that the latter involves repeatedmeasurements throughout
he trial, while the former is based on just one ﬁnal measurement.
owever, the ratio of means is also sometimes less powerful than
he odds ratio (Fig. 3), despite the fact that it too is based only on29 (2011) 3686–3694 3691
a single ﬁnal measurement. Our interpretation is that the negative
binomial involves the estimation of two parameters, rather than
one for the binomial and that estimation of k, when it has a small
value, leaves less information for estimation of the means than is
available for the odds ratio after dichotomizing the infection inten-
sity data. However, in such cases the differences between the effect
measures are small (Fig. 3).
It is striking that the beneﬁt, if any, of the ratio ofmeans depends
crucially on the values assumed for the negative binomial k param-
eter. The simplest assumption, which we have made previously
[24], is to assume that k is ﬁxed and, in particular, that it is equal
in the two arms of the trial. In practice, however, k is often found
to increase with the mean [39]. Incorporating such patterns may
reduce the statistical beneﬁt of the ratio of means over the other
effectmeasures.Moreover, ifk is assumedﬁxed then, for largemean
values, the required sample size would depend largely on the ratio
of means and hardly at all on their individual magnitudes, which
would be misleading when the assumption fails. In summary, val-
ues for k should be chosen carefully because the resulting sample
sizes could vary greatly depending on the assumption made. Ide-
ally, baseline studies would estimate mean and k in the vaccine
study site, as well as the relation between these parameters across
geographically deﬁned subregions.
The current methods could be extended quite easily to look
at the proportion over a given non-zero value, e.g. the thresh-
olds used by the World Health Organization to deﬁne moderate
or heavy infection intensity [40]. However, some other potential
endpoints would require altogether different approaches. In par-
ticular, we did not consider the median infection intensity, largely
because the majority of trial participants in each arm may well
remain uninfected, in which case their median infection intensi-
ties would be zero. Nor did we consider the Williams mean [41],
which is calculated by adding one to the parasite counts or inten-
sities, then calculating the geometric mean, then subtracting one.
This measure, sometimes loosely called the geometric mean [42],
is dependent on the measurement scale [43] and, in the presence
of a large proportion of zeros, has the additional problem that the
desired normal (Gaussian) distribution [44] will not be obtained.
Statistical convenience aside, the mean parasite intensity is more
biologically relevant than these other intensity measures in that it
is proportional to the total number of parasites present in the pop-
ulation. For example, in the case of hookworm, the mean infection
intensity is proportional to the total number of eggs being excreted,
which in turn is likely tobe closely related to transmission intensity.
It would be possible to obtain an algebraic expression for the
differences in Z statistics between the candidate effect measures,
rather than calculating them numerically andmaking assessments
from graphs. However, although the equations in Appendix A are
not mathematically sophisticated, they are rather long, especially
bearing in mind that each occurrence of p or  is a function of 
and k, which are the starting points of the analysis. Hence it seems
unlikely that pursuing the difference in Z statistics algebraically
would bemore informative than the graphical approach used here.
Basing the analysis on larger stool sample volumes (or more
replicate samples taken per person at each examination round)will
increase the mean (but not k, see Appendix C) and so will increase
the power, since the denominator of Zmean is reduced (Appendix A).
The extent of this beneﬁt will depend on the other parameters in
the equation. Similarly, the stool sample volumes used by alterna-
tive parasite counting methods may inﬂuence the choice between
them, e.g. Kato-Katz or McMaster for fecal egg counts. For some
species, there may also be a choice of counting different forms of
the parasite, e.g. adult worms or eggs, and these will, in general,
have differing statistical powers depending on their distributions.
The second objective of the current work was to judge the
extent towhich population-level effects of trial activities – clearing
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aseline infections and inoculating some people with a vaccine
oped to be efﬁcacious – are likely to reduce the force of infec-
ion and hence the statistical power of the trial. The results from
urmodel suggest that these effects are likely to beunimportant for
accines with low tomiddling efﬁcacy (say, up to 50%). Themagni-
ude of the test statistic decreases as a greater proportion of people
re included in the trial, but the reduction in power is large only for
igh efﬁcacies (Fig. 5). One additional conclusion from themodel is
reminder that the dynamics of infection may be rather slow, and,
or some species, trials may well be too short for a new equilib-
ium situation to be reached (Fig. 4). The return will be quicker for
arger values of the basic reproduction number (R0), shorter-lived
arasites [31], and trial designs in which a smaller proportion of
esidents receive an effective vaccine.
This model is a simple extension of an existing one [22]. It was
ecessary to extend the model to represent the various groups in a
accine trial, but some features of the previous model were omit-
ed. In particular, we did not consider the fact that some species
re dioecious and so may fail to reproduce due to lack of a mate
n their human host. This may become an important constraint at
ow infection intensities. Nor did we allow for the time taken to
evelop to sexual maturity in the human host. For hookworm, this
eriod is approximately 6–8weeks [45] which is likely to be short
ompared to the time needed to return to equilibrium, so this fac-
or is likely to be relatively unimportant. We also assumed random
ixing – i.e. that an uninfected person is equally likely to acquire
nfection from any of the infected people in the population –which
s a simpliﬁcation, possibly an over-simpliﬁcation in some cases.
The vaccine efﬁcacy was expressed as a constant factor ( )
pplied to the rate of acquisition of infection, in terms of numbers
f adultworms.We did not look at othermodes of action, e.g. a pro-
ortion ( ) of the vaccine arm being completely protected and the
emainder receiving no protection [46]. The present work could
e modiﬁed to divide the vaccine arm into two groups, although
t seems unlikely that the mass effects would be changed greatly.
nother limitation is the assumption of lack of waning of vaccine
fﬁcacy. Rapid waning would clearly have a major impact, espe-
ially in the vaccine arm, although quantifying this would, given
urrent knowledge, be rather speculative.
The model is simpler than the microsimulation approach used
n a related study [47] which focussed on the effects of differential
accine efﬁcacy in groups with different infection intensity. The
arlier study estimated vaccine effects over time on both infec-
ion and morbidity, while the current paper concentrates on how
ost efﬁciently to measure vaccine effects on infection. We have
ssumed that thenegativebinomial dispersionparameter (k) varies
ith the mean, rather than staying constant. The former assump-
ion is better supported by available data and is likely to crucially
ffect statistical power.
We have only considered a very simple trial design, with partic-
pants individually randomized between vaccine and control arms.
ass effects could be reduced by using other designs, in particu-
ar cluster-randomization [48]. However, our results suggest that,
f only a relatively small proportion of the study population receive
he vaccine, then such effects are, in any case, likely to be relatively
nimportant. If the study population is children then such effects
re likely to be even less because, although age does not appear
xplicitly in the model presented here, children will tend to have
nfections of lower intensity.
We conclude that mean parasite intensity is a feasible endpoint
or later phase vaccine trials. In addition, although the trial inter-ZRR =
log(1
(T/m)
√
(1/n)((((e1T/m − 1)(1 − e−1T/m))/(21(1 −29 (2011) 3686–3694
ventions will reduce the force of infection in the study area, the
resulting loss of statistical power is unlikely to be important unless
there is a combinationofhighvaccineefﬁcacyandahighproportion
of population enrolment. Finally, the magnitude of some results
depended greatly on whether the negative binomial k parameter
was assumed ﬁxed or allowed to vary with the mean, and such
assumptions should be considered carefully when planning trials.
Appendix A. Algebraic relations between the candidate
trial endpoints and effect measures
The egg counts are assumed to follow a negative binomial dis-
tribution with parameters  (the mean) and k. This distribution
applies to the number of parasites seen, before conversion to a
standard amount such as eggs per gram. We denote the mean egg
counts, at the end of the trial follow-up, in the intervention and
control arms of the trial by 1 and 0 respectively. Similarly, the
second parameter of the negative binomial distribution is denoted
by k1 and k0 respectively in the two arms. In some caseswe assume
k1 = k0. Each arm is assumed to have data on n participants.
To compare the mean parasite intensity between the interven-
tion and control arms, we consider the test statistic Zmean, which
is the difference in log-means divided by the standard error of this
difference [24]:
Zmean = log(1) − log(0)√
var(log(1) − log(0))
= log(1) − log(0)√
(1/n)((1/1) + (1/0) + (1/k1) + (1/k0))
The prevalence of infection (p) is related to the negative bino-
mial parameters as follows [22]:
Prevalence = Probability (positive) = p(,k) = 1 −
(
k
+ k
)k
Hence from the means in the two arms (0 and 1), and k, we
can derive the prevalences (p0 and p1), and so the odds of being
positive, in the two arms at the end of the trial. From this we derive
the test statistic for the odds ratio between the arms ZOR, which is
the ratio of the difference in log-odds divided by the standard error
of this difference [49]:
Zor =
log
(
p1
1−p1
)
− log
(
p0
1−p0
)
√
var
(
log
(
p1
1−p1 − log
(
p0
1−p0
)) = log
(
p1
1−p1
)
− log
(
p0
1−p0
)
√
1
n
(
1
p1(1−p1)
+ 1p0(1−p0)
)
We can relate the time to ﬁrst infection to the other endpoints via
the rate () at which trial participants become positive. If the trial
lasts time T, then the proportion positive at the end of the trial (p)
is related to ,  and k as follows:
 = − log(1 − p)
T
= k log(k/(+ k))
T
For many parasites, the time of infection is not marked by
speciﬁc symptoms and so will not generally be observed exactly.
Rather, the infection will be detected at the next follow-up exam-
ination. This reduces the precision of the rate estimation. If we
assume that there are m examinations evenly spaced throughout
the trial, then the sampling error can be quantiﬁed as a decreasing
function of m, as can the Fisher information I of the incidence rate
 [30]. The Fisher information for the natural logarithm of the rate
Ilog() is I divided by the square of the differential of the logarith-
2mic function, so Ilog() = I. Hence we obtain the Z statistic for the
rate ratio (1/0):
) − log(0)
e−1T ))) + (((e0T/m − 1)(1 − e−0T/m))/(20(1 − e−0T ))))
ccine
t
w
o
t
A
i
i
p
a
t
f
r
d
a
t
g
c
t
c
i
f
t
t
w
t
t
f
t
v
A
p
o
h
a
r
r
n
[
p
s
b
o
m
e
t
E
[N. Alexander et al. / Va
We assume T=1 so that the incidence rates are per study dura-
ion. Since p0, p1,0 and 1 can all be expressed in terms of and k,
e can now directly compare the magnitudes of the test statistics
f the three effect measures: the ratio of means, the odds ratio, and
he incidence rate ratio.
ppendix B. Mathematical model of the impact of trial
nterventions on the force of infection
Weuse amodel of AndersonandMay [22] for themean infection
ntensity , which now refers to the number of adult worms per
erson (rather than eggs counted per sample):
d
dt
= (ω +ω1)(R0f () − 1) (A.1)
In this equation, R0 is the basic reproduction number, ω and ω1
re the death rates of humans and adult worms, respectively, and
he following term
() =
(
1 + (1 − d)
k
)−k−1
epresentsdensitydependencevia aparameterd.More speciﬁcally,
is the ratio by which per capita egg output decreases per extra
dult. We impose density dependence (d /= 1) because otherwise
he model has no stable non-zero equilibrium.
We divide the population of the trial study area into three
roups. A proportion  are in the trial, half each in the active vac-
ine and control arms. People in both arms are assumed to have
heir infections cleared at the start of the trial. The third group,
omprising a proportion 1−, are not in the trial and receive no
ntervention. The rates at which the three groups acquire infection
rom each other are assumed to be proportional to the fraction of
hepopulationwhich theycomprise. Finally, thevaccine is assumed
o reduce acquisition of infection, in terms of numbers of adult
orms, by a factor  . So we can write the following equation for
he mean 1 in vaccine arm:
d1
dt
= (ω +ω1)
(
R0 
(

2
f (1)1 + 2 f (0)0 + (1 − )f (2)2
)
−1
)
Here, 0 and 2 are the means in the control arm and the non-
rial groups respectively. The equation for the placebo has a similar
orm but without  . The non-trial group has the same equation as
heplacebo arm, but differs in that its initial value is the equilibrium
alue * rather than 0.
ppendix C. Effect of sample volume on negative binomial
arameters
This paper generally assumes that over time, or between arms
f the trial, higher values of mean egg count are associated with
igher values of thenegativebinomial dispersionparameterk. Such
n association does not apply, however, when the increased mean
esults simply from counting a larger sample volume per person.
It iswell knownthat thesumofn independentnegativebinomial
andom variables, each with parameters 0 and k0, itself follows a
egative binomial distribution with parameters n×0 and n× k0
50]. Hence one might think that, for example, doubling the sam-
le volume read per sample – e.g. by doubling the number of fecal
lides – would double both  and k. This is not the case, however,
ecause the additional sample is not independent of the original
ne, contrary to the premise of the calculation.
The negative binomial distribution can be derived as a gamma
ixture of Poissons [51]: within each person the stool (or blood,
tc.) is sampled uniformly (a Poisson process with ﬁxedmean), but
hebetween-personvariation ismodelledby a gammadistribution.
quivalently, each person’s Poisson variate has a mean equal to
[
[29 (2011) 3686–3694 3693
the populationmean,multiplied a ‘randomeffect’with distribution
gamma(k)/k, andhencemean1andvariance1/k [52]. Increasing the
sample volume increases the mean but not the person’s random
effect: it’s not possible to reduce between-person heterogeneity by
processing larger samples.
This can be veriﬁed empirically by simulating a given number of
negative binomially distributed parasite counts, then halving each
sample by allocating eachparasite at randomtooneof two subsam-
ples. The estimated k parameter for each of the subsamples is the
same (within sampling error) as that for the larger sample. AsMor-
ton and Baird express this, the dispersion parameter is ‘invariant
under random thinning’ [53].
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